Why the study?
Although in vitro data suggested rivaroxaban may affect platelet function, little was known about the clinical impact or dose-dependency of this potential antiplatelet effect.
Does rivaroxaban at various clinical doses inhibit direct platelet aggregation in adult patients?
Does rivaroxaban at various clinical doses inhibit direct platelet aggregation in adult patients?
Rivaroxaban does not directly affect platelet aggregation at clinical doses, suggesting its antithrombotic effects are solely mediated through factor Xa inhibition.
No takes yet. Share an insight, caveat, or question.
No direct antiplatelet effect seen with rivaroxaban; challenges in vitro suggestions and leaves open clinical relevance of thrombin inhibition.
Hernández‐Juárez et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: